KEITH L. BROWNLIE - Corporate Board Profile

Celldex Therapeutics, Inc.

Filing Date	Source Excerpt
2017-04-28	Keith L. Brownlie was nominated for election to our Board of Directors in March 2017. Following the 2017 Annual Meeting, Mr. Brownlie is expected to be appointed to the Audit Committee.
2018-04-30	Keith L. Brownlie Age 65 Year First Became Director 2017 The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, Larry Ellberger and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2017. Keith L. Brownlie Fees Earned or Paid in Cash $53,397 Stock Awards $23,200 Option Awards $35,795 Total $112,392
2019-04-26	Keith L. Brownlie became a director of Celldex in June 2017. He is Chair of the Audit Committee. The Audit Committee consists of Keith L. Brownlie, Chair, Larry Ellberger and Harry H. Penner, Jr. The Audit Committee met seven times during 2018. Compensation for 2018 was $94,219.
2020-04-28	Keith L. Brownlie became a director of Celldex in June 2017. The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Keith L. Brownlie and Karen L. Shoos. The following table summarizes the annual compensation for our non-employee directors during 2019. Keith L. Brownlie received $57,804 in fees and $9,386 in option awards, totaling $67,190.
2021-04-27	Keith L. Brownlie became a director of Celldex in June 2017. Mr. Brownlie was employed by the accounting firm Ernst & Young LLP from 1974 to 2010. ... The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Keith L. Brownlie and Karen L. Shoos. ... The following table summarizes the annual compensation for our non-employee directors during 2020. Keith L. Brownlie Fees Earned or Paid in Cash $59,000 Option Awards $87,586 Total $146,586.
2022-04-26	Keith L. Brownlie became a director of Celldex in June 2017. Mr. Brownlie was employed by the accounting firm Ernst & Young LLP from 1974 to 2010. ... The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Keith L. Brownlie and Karen L. Shoos. ... The following table summarizes the annual compensation for our non-employee directors during 2021. ... Keith L. Brownlie Fees Earned or Paid in Cash ($) 59,000 Option Awards ($) 260,828 Total ($) 319,828.
2023-04-25	Keith L. Brownlie 70 2017 1 The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2022. Keith L. Brownlie Fees Earned or Paid in Cash ($) 61,979 Option Awards ($) 231,866 Total ($) 293,845
2024-04-25	The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... Each member of the Audit Committee is “independent” as that term is defined in the rules of the Securities and Exchange Commission (the “SEC”) and the applicable NASDAQ listing standards. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date).